伊马替尼对免疫功能和造血系统影响的研究进展
摘要
伊马替尼通过选择性竞争结合ab1酪氨酸蛋白激酶的ATP结合位点而有效地治疗慢性粒细胞白血病（CML）。和其他药物相比，伊马替尼能够使CML患者获得更高的细胞遗传学反应和持久的缓解率，且耐受性好，不良反应轻。它已被越来越多地用于治疗Ph＋染色体的白血病和其他恶性疾病。但是，近年来研究表明伊马替尼对免疫和造血系统有抑制作用，本文就国外在这方面的研究进展作一简要综述。
出处
《国际输血及血液学杂志》
CAS
2007年第1期66-69,共4页
International Journal of Blood Transfusion and Hematology
参考文献24
-
1Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res,2003,9(3):976-980.
-
2Baskaynak G, Kreuzer KA, Schwarz M, et ah Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. Eur J Hematol, 2003,70(4) : 231-234.
-
3Tybulewicz VL, Crawford CE, Jackson PK, et ah Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl protooncogene. Cell, 1991,65(7):1153-1163.
-
4Schwartzberg PL, Stall AM, Hardin JD, et ah Mice homozygous for the ablml mutation show poorviability and depletion of selected B and T cell populations. Cell, 1991,65(7) :1165-1175.
-
5Appel S, Boehmler AM, Grunebach F, et al. lmatinib mesylate affects the development and function of dendritic cells generated from CD34- peripheral blood progenitor cells. Blood, 2004,103 (2) :538-544.
-
6Taieb J, Maruyama K, BOrg C, et ah Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood, 2004,103(5) : 1966-1967.
-
7Boissel N, Rousselot P, Raffoux E, et ah Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation. J Leukoc Biol, 2006,79 (4) : 747-756.
-
8Sato N, Narita M, Takahashi M, et ah The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol, 2003,21 (2) : 67-75.
-
9Mohty M, Jourdan E, Mami NB, et al. Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia. Blood, 2004, 103 (2) : 4666-4668.
-
10Cwynarski K, Laylor R, Macchiarulo E, et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia, 2004, 18(8):1332-1339.
-
1张明智,宋永平,范魁生.重组人粒细胞巨噬细胞集落刺激因子治疗骨髓抑制[J].新药与临床,1995,14(1):38-40. 被引量：2
-
2王月英,吴红英,李德冠,张恒,刘强,路璐,王小春,王汝勤,孟爱民.E838保护放化疗小鼠造血功能的疗效观察[J].陕西医学杂志,2009,38(11):1443-1444. 被引量：3
-
3血小板生成素的新角色——促进健康干细胞生成[J].国际药学研究杂志,2013,40(2):254-254.
-
4张燕萍,陈嘉林,潘华珍.血细胞生成中的信号传递通路及其调控[J].中国实验血液学杂志,1998,6(3):161-167. 被引量：4
-
5黄世杰.治疗血细胞生成疾患的新候选药[J].国外医学（药学分册）,2004,31(1):58-58.
-
6陈江水.长时间吸入N_2O复合七氟醚对骨髓功能的抑制作用研究[J].河北医科大学学报,2013,34(6):723-725.
-
7顾士荣.警惕药物引起血液病的发生[J].中国现代药物应用,2008,2(10):125-125.
-
8刘庆.新的二肽基肽酶IV抑制剂Sulphostin[J].国外医药（抗生素分册）,2005,26(6):284-285.
-
9徐祖琼,孙雪梅.BCR—ABL激酶突变与酪氨酸激酶抑制剂的研究进展[J].中华血液学杂志,2010,31(9):644-646. 被引量：2
-
10LI Yu-feng,DENG Zhi-kui,XUAN Heng-bao,ZHU Jia-bin,DING Bang-he,LIU Xiao-ning,CHEN Bao-an.Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy[J].Chinese Medical Journal,2009(12):1413-1417. 被引量：3
